Improve Research Reproducibility A Bio-protocol resource
Concise Method
tooltip

MSI analysis

AH Anna‐Lina Herz
SW Sarah Wisser
MK Meike Kohlruss
JS Julia Slotta‐Huspenina
MJ Moritz Jesinghaus
BG Bianca Grosser
KS Katja Steiger
AN Alexander Novotny
AH Alexander Hapfelmeier
TS Thomas Schmidt
MG Matthias M Gaida
WW Wilko Weichert
GK Gisela Keller
ask Ask a question
Favorite

Tumours had been analysed for MSI previously using the Bethesda panel encompassing two mononucleotide repeats (BAT25 and BAT26) and three dinucleotide repeats (D2S123, D5S346, and D17S250) [3, 8]. Tumours with only instability at two dinucleotides were additionally analysed using three mononucleotides (NR‐21, NR‐24, and NR‐27). Tumours were classified as MSI‐H if at least two markers of the Bethesda panel were unstable including at least one unstable mononucleotide marker or if at least two of the five mononucleotide markers showed instability essentially as described [9].

Tumours showing instability only at one marker or only at two dinucleotide markers of the Bethesda panel were classified as MSI‐L. Microsatellite stable (MSS) tumours did not show any instability.

Copyright and License information:  ©2022 The Authors. published by The Pathological Society of Great Britain and Ireland & John Wiley & Sons, Ltd.
This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A